Form SC 13G/A Theravance Biopharma, Filed by: VANGUARD GROUP INC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Leerink Partners Reiterates Market Perform Rating on Theravance Biopharma (TBPH)
November 13, 2024 9:39 AM ESTLeerink Partners analyst David Risinger reiterated a Market Perform rating and $10.00 price target on Theravance Biopharma (NASDAQ: TBPH).
The analyst comments "TBPH reported strong 3Q24 results, including total revenue 12% above consensus and operating income 13% above, but EPS 5% below largely due a non-cash impairment... More
